Objectif Obesity is one of the most serious and fast-growing health problem in the European Union, and a leading cause of diabetes. The main barrier for approval of an anti-obesity drug is the safety requirements. We propose to overcome this barrier by discovering phenotypes and biomarkers that identify subsets of patients with safe and efficacious responses to drugs, and by identifying new indications of existing drugs with proven safety profiles. To be approved, anti-obesity drugs need to show a decrease in abdominal fat. We focus on approaches targeting directly abdominal fat cells. In the last years only the cannabinoid CB1 receptor antagonist Rimonabant has been approved as a therapeutic agent to combat complicated obesity. Research performed with this drug has clearly revealed a role for the endogenous cannabinoid system in controlling energy homeostasis. However, its utility is limited to a restricted set of patients. A new phenotype and/or biomarker may identify responsive patients with good safety profiles. This proposal aims to discover novel or improved treatments in the shortest possible timeframe through three synergistic Specific Aims: 1) Clinical phenotyping of obese patients to identify those that would benefit from existing therapies such as Rimonabant. 2) Discover biomarkers for subsets of obese patients that may correlate with therapeutical outcomes. These biomarkers will be discovered by a novel approach called Combinatorial Cytomic Biomarkers developed by OrphaMed, applied to cells from two physiologically interlinked sources: blood and abdominal-fat samples, extracted from the above phenotyped patients. 3) Identify new indications of existing drugs, alone or in combination, with potential anti-obesity efficacy by lowering the fat content and the glucose uptake of abdominal fat cells, which would be expected to improve carbohydrate/lipid metabolism and lower body weight, extracted from the above phenotyped patients. This will be accomplished by screening approximately 2.000 known drugs against these fat cells using the novel technology platform “ExviTech” from OrphaMed. Candidates would be evaluated in animal models of obesity. Champ scientifique medical and health sciencesclinical medicineendocrinologydiabetesnatural sciencesbiological sciencesbiochemistrybiomoleculeslipidsmedical and health sciencesbasic medicinephysiologyhomeostasismedical and health scienceshealth sciencesnutritionobesity Mots‑clés Reprofiling anti-obesity drugs combinational cytomic biomarkers obesity biomarkers Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH-2007-1.1-4 - SME-driven collaborative research projects for developing tools and technologies for high-throughput research HEALTH-2007-2.4.3-6 - Nutritional signals and the development of new diabetes/obesity therapeutic agents Appel à propositions FP7-HEALTH-2007-B Voir d’autres projets de cet appel Régime de financement CP-TP - Collaborative Project targeted to a special group (such as SMEs) Coordinateur FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD Contribution de l’UE € 594 005,00 Adresse CALLE SEVERO OCHOA 35, PARQUE TECNOLOGICO DE ANDALUCIA 29590 MALAGA Espagne Voir sur la carte Région Sur Andalucía Málaga Type d’activité Research Organisations Contact administratif Fernando Rodriguez De Fonseca (Dr.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée Participants (6) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire VIVIA BIOTECH S.L. Espagne Contribution de l’UE € 2 723 786,00 Adresse C SANTIAGO GRISOLIA 2 OFICINA 205 28760 TRES CANTOS MADRID Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Olivia De La Lama Noriega (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE France Contribution de l’UE € 505 440,00 Adresse RUE DE TOLBIAC 101 75654 Paris Voir sur la carte Région Ile-de-France Ile-de-France Paris Type d’activité Research Organisations Contact administratif Giovanni Marsicano (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée JOHANNES GUTENBERG-UNIVERSITAT MAINZ Allemagne Contribution de l’UE Aucune donnée Adresse SAARSTRASSE 21 55122 Mainz Voir sur la carte Région Rheinland-Pfalz Rheinhessen-Pfalz Mainz, Kreisfreie Stadt Type d’activité Higher or Secondary Education Establishments Contact administratif Beat Lutz (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA Italie Contribution de l’UE € 508 860,00 Adresse VIA ZAMBONI 33 40126 Bologna Voir sur la carte Région Nord-Est Emilia-Romagna Bologna Type d’activité Higher or Secondary Education Establishments Contact administratif Alessandra Malavolta (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée UNIVERSIDAD DE SANTIAGO DE COMPOSTELA Espagne Contribution de l’UE € 505 919,00 Adresse COLEXIO DE SAN XEROME PRAZA DO OBRADOIRO S/N 15782 Santiago De Compostela Voir sur la carte Région Noroeste Galicia A Coruña Type d’activité Higher or Secondary Education Establishments Contact administratif Fernando Sedano Arnaez (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ Allemagne Contribution de l’UE € 561 402,00 Adresse Langenbeckstrasse 1 55131 Mainz Voir sur la carte Région Rheinland-Pfalz Rheinhessen-Pfalz Mainz, Kreisfreie Stadt Type d’activité Higher or Secondary Education Establishments Contact administratif Uta Veith (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée
